Seeking Alpha

More on St. Jude Medical (STJ +0.8%) Q4: net profit -4% to $120M despite cutting SG&A costs...

More on St. Jude Medical (STJ +0.8%) Q4: net profit -4% to $120M despite cutting SG&A costs by 18% and R&D spending by 11%. Cardiac rhythm management sales -6% to $682M, atrial fibrillation products +10% to $239M, total cardiovascular sales flat at $338M. Expects Q1 EPS of $0.91-0.93 vs consensus of $0.89 and 2013 EPS of $3.68-3.73 vs $3.62.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)